Targeting the TGF-β signaling pathway for resolution of pulmonary arterial hypertension

Targeting the TGF-β signaling pathway for resolution of pulmonary arterial hypertension

Yes === Aberrant transforming growth factor-β (TGF-β) signaling activation is linked to pulmonary arterial hypertension (PAH). BMPR2 mutations perturb the balance between bone morphogenetic protein (BMP) and TGF-β pathways, leading to vascular remodeling, narrowing of the lumen of pulmonary vasculat...

Full description

Bibliographic Details
Main Authors: Sharmin, Nahid, Nganwuchu, Chinyere C., Nasim, Md. Talat
Language:en
Published: 2021
Subjects:
Pulmonary arterial hypertension
TGF-β
BMP
Pulmonary vasculature
ALK5 inhibitor
Online Access:http://hdl.handle.net/10454/18507
Description
Summary:Yes === Aberrant transforming growth factor-β (TGF-β) signaling activation is linked to pulmonary arterial hypertension (PAH). BMPR2 mutations perturb the balance between bone morphogenetic protein (BMP) and TGF-β pathways, leading to vascular remodeling, narrowing of the lumen of pulmonary vasculature, and clinical symptoms. This forum highlights the association of the TGF-β pathway with pathogenesis and therapeutic approaches. === Research carried out at Nasim laboratories is funded by GrowMedtech, the Royal Society, the Commonwealth Scholarship Commission (CSC) and the University of Bradford (UoB). N.S. is funded by the CSC and C.C.N. is partly funded by the UoB. === The full-text of this article will be released for public view at the end of the publisher embargo on 06 May 2022.

Similar Items